WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced a collaboration with Shalesh Kaushal, M.D., Ph.D., Chairman of the Department of Ophthalmology at The University of Massachusetts Medical School (UMMS). The research collaboration will be focused on the application of RXi’s self-delivering RNAi (sd-rxRNA™) compounds for ocular diseases such as age-related macular degeneration, the leading cause of blindness in Americans over 55 years of age.
